Multiple Sclerosis and Related Disorders, Journal Year: 2024, Volume and Issue: 88, P. 105702 - 105702
Published: June 5, 2024
Language: Английский
Cell stem cell, Journal Year: 2023, Volume and Issue: 30(5), P. 512 - 529
Published: April 20, 2023
Language: Английский
Citations
90
Bone Marrow Transplantation, Journal Year: 2022, Volume and Issue: 57(7), P. 1055 - 1062
Published: May 16, 2022
Abstract Autoimmune diseases (ADs) represent a heterogenous group of complex with increasing incidence in Western countries and are major cause morbidity. Hematopoietic stem cell transplantation (HSCT) has evolved over the last 25 years as specific treatment for patients severe ADs, through eradication pathogenic immunologic memory profound immune renewal. HSCT ADs is recently facing unique developmental phase across transplant centers. This review provides comprehensive overview recent evidence developments area, including fundamentals preclinical research, clinical studies neurologic, rheumatologic gastroenterologic diseases, which indications at present, along rarer indications. Moreover, we describe interwoven challenges delivering more advanced cellular therapies, exploiting mesenchymal cells, regulatory T cells potentially CAR-T affected by ADs. Overall, discuss past current indications, efficacy, associated risks benefits, future directions therapies severe/refractory integrating available literature European Society Blood Marrow Transplantation (EBMT) registry data.
Language: Английский
Citations
57
Multiple Sclerosis and Related Disorders, Journal Year: 2024, Volume and Issue: 83, P. 105435 - 105435
Published: Jan. 7, 2024
Language: Английский
Citations
12
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15
Published: Jan. 7, 2025
Autoimmune retinopathy (AIR) is a rare, potentially blinding retinal disease that remains challenging condition to manage when resistant conventional immune-modulatory approaches. We report clinical and electrophysiological improvement in 49-year-old patient who underwent an autologous hematopoietic stem cell transplant (aHSCT) for thymoma-associated AIR after experiencing progressive despite receiving periocular systemic steroids, mycophenolate mofetil, baricitinib, tacrolimus, bortezomib, rituximab, plasmapheresis, intravenous immunoglobulin. The aHSCT had two stages: (i) peripheral blood harvest following mobilization with cyclophosphamide granulocyte colony-stimulating factor, (ii) conditioning regimen cyclophosphamide, anti-thymocyte globulin high-dose therapy, followed by infusion of 5.74 million cells. Symptoms photopsia rapidly abated undergoing aHSCT, objective investigations structure function similarly demonstrated improvement. At 22 months' follow-up, she continued demonstrate the durability response. present suggests judiciously selected patients, HSCT may provide rescue option refractory AIR. Further cases are needed confirm these results.
Language: Английский
Citations
1
Neurology and Therapy, Journal Year: 2022, Volume and Issue: 11(4), P. 1553 - 1569
Published: July 28, 2022
In 1995, the use of autologous hematopoietic stem-cell transplantation (AHSCT), which was previously used to treat hematological tumors, introduced for severe autoimmune diseases such as multiple sclerosis (MS). AHSCT has proven its safety over past few years due technical advances and careful patient selection in transplant centers. While most studies have reported that led decreased Expanded Disability Status Scale (EDSS) scores, some patients increased EDSS scores following procedure. Given contradictory results, we aimed conduct a comprehensive systematic review meta-analysis investigate efficacy AHSCT.PubMed, Web Science, Scopus were searched March 2022 using predefined search strategy. We included cohort studies, clinical trials, case-control case series investigated or with MS. PICO present study defined follows: problem population (P): MS; intervention (I): AHSCT; comparison (C): none; outcome (O): safety.After two-step process, 50 total 4831 MS our study. Our analysis showed significant decrease score after treatment (standardized mean difference [SMD]: -0.48, 95% CI -0.75, -0.22). Moreover, annualized relapse rate also significantly reduced compared pretreatment period (SMD: -1.58, -2.34, -0.78). The pooled estimate progression-free survival 73% (95% 69%, 77). Furthermore, 81% who received remained relapse-free 76%, 86%). Investigating event-free survival, reflects absence any disease-related event, 63% 54%, 73%). Also, MRI activity-free 89% 84%) among low heterogeneity. New lesions seem appear nearly 8% underwent 4%, 12%). 68% experience no evidence disease activity (NEDA) 59%, overall 94% 91%, 96%). addition, 4% died from transplant-related causes 2%, 6%).Current data encourages broader application treating while still considering proper methods. increasing knowledge expertise field therapy, become safer approach
Language: Английский
Citations
23
Journal of Neurology, Journal Year: 2022, Volume and Issue: 269(7), P. 3937 - 3958
Published: April 11, 2022
Autologous haematopoietic stem cell transplantation (aHSCT) is gaining traction as a valuable treatment option for patients affected by severe multiple sclerosis (MS), particularly the relapsing-remitting form. We describe current literature in terms of clinical trials, observational and retrospective studies, well immune reconstitution following transplantation, with focus on conditioning regimens used transplantation. The evidence base predominantly consists non-randomised, uncontrolled trials or data from cohorts, i.e. very few randomised controlled trials. Most often, intermediate-intensity are used, promising results both myeloablative lymphoablative strategies, that low high intensity. Efficacy which likely secondary to restored tolerance, is, therefore, not clearly dependent intensity regimen. However, regimen may influence response Heterogeneity among studies hinders synthesis articles assessing post-aHSCT system changes. Factors associated better outcomes were lower Kurtzke Expanded Disability Status Scale, MS, younger age, shorter disease duration at baseline, supports guidance patient selection proposed European Society Blood Marrow Transplantation. Interestingly, described progressive MS some be worth taking into account when considering options active, disease. Of note, significant proportion develop autoimmune alemtuzumab-containing highest incidence.
Language: Английский
Citations
19
Cell Communication and Signaling, Journal Year: 2023, Volume and Issue: 21(1)
Published: Nov. 29, 2023
Abstract Natural killer (NK) cells are essential components of the innate lymphoid cell family that work as both cytotoxic effectors and immune regulators. Accumulating evidence points to interactions between NK central nervous system (CNS). Here, we review basic knowledge biology recent advances in their roles healthy CNS pathological conditions, with a focus on normal aging, autoimmune diseases, neurodegenerative cerebrovascular infections. We highlight crosstalk diverse types potential value novel therapeutic targets for diseases.
Language: Английский
Citations
12
Heliyon, Journal Year: 2024, Volume and Issue: 10(11), P. e31744 - e31744
Published: May 31, 2024
BackgroundMultiple sclerosis (MS) is a heterogeneous autoimmune disease, with rapidly evolving body of literature on disease-modifying therapy (DMT) that urgently needs to be synthesized and regularized.MethodsThe original material used for the analysis was obtained from Web Science Core Collection (WoSCC) in Citation Index Expanded Edition (SCI-E). The data accessed through VOSviewer, Citespace, R package "Bibliometrix", Scimago Graphica visualization. Among them, clustering algorithm based Largest Likelihood Ratio (LLR) burst citation key.ResultsAs November 6th, 2022, 4142 publications related emerging therapies (e-DMT) MS, 6521 traditional (t-DMT) 1793 cross-cutting (I-DMT) MS were included analysis, respectively. Publications DMT analyzed descriptively (for three subjects: country, institution, author) predictively two keywords references) separately according sections: e-DMT, t-DMT, I-DMT. Topics still have relevant reference output as 2022 include safety Coronavirus disease 2019 (COVID-19) mRNA vaccination, therapeutic inertia (TI), cladribine tablets, autologous hematopoietic stem cell transplantation (aHSCT), progressive multiple sclerosis, pediatric sclerosis.ConclusionThe future research focus combination trial or cross-trial various treatment methods improve development individualized plans patients. exact contents frontiers are but not limited ocrelizumab, fingolimod other monoclonal antibodies, fumaric acid ester, tablet, aHSCT, interventions randomized controlled trials (RCTs); impact COVID-19 vaccination patients; TI, patient adherence, medical management issues; continued exploration biomarkers more accurate classification existing clinical indication classification.
Language: Английский
Citations
4
Infectious Diseases Now, Journal Year: 2025, Volume and Issue: unknown, P. 105050 - 105050
Published: March 1, 2025
Language: Английский
Citations
0
Advances in experimental medicine and biology, Journal Year: 2025, Volume and Issue: unknown, P. 301 - 323
Published: Jan. 1, 2025
Language: Английский
Citations
0